Literature DB >> 29882396

Comparison of patients with hepatic encephalopathy and those with gastric varices before and after balloon-occluded retrograde transvenous obliteration.

Tsuyoshi Ishikawa1, Ryo Sasaki1, Tatsuro Nishimura1, Takashi Matsuda1, Masaki Maeda1, Takuya Iwamoto1, Issei Saeki1, Isao Hidaka1, Taro Takami1, Isao Sakaida1.   

Abstract

AIM: To compare the clinical characteristics of patients with hepatic encephalopathy (HE) and those with gastric varices (GV) before and after balloon-occluded retrograde transvenous obliteration (BRTO).
METHODS: Eighty cirrhotic patients who underwent BRTO, including 42 men and 38 women, and whose mean age was 68 years, comprised the HE (n = 18) and GV (n = 62) groups. The patients' data before and 1 month after BRTO were analyzed.
RESULTS: Before BRTO, the groups did not differ in their portal flow volume (PFV) or hepatic venous pressure gradient (HVPG). The portal vein (PV) was narrower and the splenic vein (SpV) was wider in the HE group than in the GV group. The SpV flow was hepatofugal in 75.0% of HE patients and hepatopetal in 92.6% of GV patients. The Child-Pugh (CP) score of the HE group was significantly higher than that of the GV group pre-BRTO. After BRTO, the PFV and HVPG increases in the HE group equaled those in the GV group, and the PV dilation was similar in both groups. Conversely, the SpV was significantly contracted for HE patients, but significantly dilated for GV patients. Postoperatively, the SpV flow was hepatopetal in all patients. Compared to that in the GV group, the CP score decreased markedly in the HE group, and no significant increases in complications occurred post-BRTO for HE patients.
CONCLUSIONS: The HE patients showed distinct portal-splenic hemodynamics before and after BRTO. Balloon-occluded retrograde transvenous obliteration markedly improved hepatic function in the HE group compared with the GV group.
© 2018 The Japan Society of Hepatology.

Entities:  

Keywords:  balloon-occluded retrograde transvenous obliteration; gastric varices; hepatic encephalopathy; portosystemic shunt

Year:  2018        PMID: 29882396     DOI: 10.1111/hepr.13199

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Successful retrograde transvenous obliteration for splenorenal shunts after liver ransplantation: Midterm results.

Authors:  Hao Wang; Haijun Gao; Guang Chen; Zhengjia Yi
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

2.  Visualization of flow dynamics in the portal circulation using 320-detector-row computed tomography: a feasibility study.

Authors:  Ken Kageyama; Akira Yamamoto; Atsushi Jogo; Shinichiro Izuta; Daisuke Himoto; Akihiko Kakimi; Etsuji Sohgawa; Yukio Miki
Journal:  Eur Radiol Exp       Date:  2021-01-12

3.  Improved Hepatic Reserve and Fibrosis in a Case of "Portal-Systemic Liver Failure" by Portosystemic Shunt Occlusion.

Authors:  Tsuyoshi Ishikawa; Ryo Sasaki; Tatsuro Nishimura; Takuya Iwamoto; Taro Takami; Takahiro Yamasaki; Isao Sakaida
Journal:  Am J Case Rep       Date:  2020-02-17

4.  Balloon-occluded retrograde transvenous obliteration for gastric varices improves hepatic functional reserve in long-term follow-up.

Authors:  Nobuo Waguri; Akihiko Osaki; Yusuke Watanabe; Tsuyoshi Matsubara; Shun Yamazaki; Hanako Yokoyama; Kiwamu Kimura; Takuya Wakabayashi; Masaki Mito; Shunta Yakubo; Rie Azumi; Junji Kohisa; Kennichi Takaku; Munehiro Sato; Kouichi Furukawa
Journal:  JGH Open       Date:  2021-11-13

Review 5.  Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.

Authors:  Hitoshi Yoshiji; Sumiko Nagoshi; Takemi Akahane; Yoshinari Asaoka; Yoshiyuki Ueno; Koji Ogawa; Takumi Kawaguchi; Masayuki Kurosaki; Isao Sakaida; Masahito Shimizu; Makiko Taniai; Shuji Terai; Hiroki Nishikawa; Yoichi Hiasa; Hisashi Hidaka; Hiroto Miwa; Kazuaki Chayama; Nobuyuki Enomoto; Tooru Shimosegawa; Tetsuo Takehara; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-07-07       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.